Absorption control agent
A temperature-responsive ionic liquid-based absorption control agent stabilizes drug permeation through the skin, addressing inconsistent delivery due to varying skin conditions, ensuring effective drug delivery across different skin barrier strengths.
Patent Information
- Application Number
- JP2023078967
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-12
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing transdermal absorption enhancers fail to control the amount of drug permeation within a certain range, varying significantly with the skin's barrier function, leading to inconsistent drug delivery in patients with varying skin conditions.
An absorption control agent containing a temperature-responsive ionic liquid that interacts with active ingredients to stabilize drug permeation, maintaining a consistent level regardless of the skin's barrier function.
The absorption control agent ensures a controlled and consistent permeation of active ingredients, addressing variability due to skin condition, suitable for patients with impaired or normal skin barrier function.
Smart Images

Figure 2024163413000001 
Figure 2024163413000002 
Figure 2024163413000003
Abstract
Description
[Technical field]
[0001] The present invention relates to an absorption control agent containing an ionic liquid. [Background technology]
[0002] Known routes of administration for pharmaceuticals include oral administration, intravenous administration, and transdermal administration, and are appropriately developed according to the physical properties and characteristics of the active ingredients.
[0003] Among them, transdermal administration has the advantage that it is easy for patients who have difficulty swallowing, such as the elderly and dementia patients, to take the medicine, it avoids side effects caused by an increase in the blood concentration of the medicine due to oral or injection administration, and it is less affected by food, so it is easy for busy patients who tend to have irregular eating habits to obtain stable drug effects, improving patient compliance.However, water-soluble drugs and drugs with large molecular weights generally have low skin permeability because they are blocked by the stratum corneum of the skin, which has a high barrier function, and drugs that can be applied to transdermal administration have been limited.
[0004] As a technique for improving the skin permeability of drugs in transdermal administration, a method using a transdermal absorption enhancer is known, and is actually used in topical skin preparations such as patches. However, by increasing the transdermal absorption of drugs using a transdermal absorption enhancer, there is a possibility that patients with weak or impaired skin barrier function, such as elderly people, children, and patients with skin diseases, may be overdosed. On the other hand, when a formulation is designed to provide an optimal drug dosage for patients with weak skin barrier function, there is a problem that the drug dosage is insufficient for patients with normal skin barrier function or patients whose skin barrier function has been normalized by treatment.
[0005] For example, Non-Patent Document 1 describes the relationship between the permeability coefficient of hydrophilic drugs such as mannitol and lipid-soluble drugs such as estradiol and the electrical resistance of the skin when surfactants, fatty acids, and fatty acid esters, which are typical transdermal absorption enhancers, are used.
[0006] Furthermore, Patent Document 1 describes a pharmaceutical composition in which the permeability of a drug through the skin, mucous membranes, etc. is improved by using a temperature-responsive ionic liquid containing an aromatic carboxylate ion and an aromatic sulfonate ion. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] International Publication No. 2021 / 070893 [Non-patent literature]
[0008] [Non-Patent Document 1] JOURNAL OF CONTROLLED RELEASE 110 (2006) 307-313. Summary of the Invention [Problem to be solved by the invention]
[0009] However, Non-Patent Document 1 describes that even in the presence of an absorption enhancer, there is a negative correlation between the electrical resistance of the skin and the permeability coefficient of the drug. Thus, when using existing absorption enhancers such as surfactants and fatty acids, there is a problem that the amount of drug permeated varies greatly depending on the condition of the skin.
[0010] Furthermore, Patent Document 1 discloses a technique for improving the amount of drug permeation through the skin or mucous membrane by using a temperature-responsive ionic liquid, but does not suggest or describe a technique for controlling the amount of permeation of active ingredients such as drugs within a certain range regardless of the strength of the barrier function of the skin or mucous membrane.
[0011] Therefore, the present invention provides an absorption control agent containing an ionic liquid for controlling the permeation amount of an active ingredient within a certain range, regardless of the strength of the barrier function of biological membranes such as skin and mucous membranes. [Means for solving the problem]
[0012] The present inventors have conducted extensive research to solve the above problems and have discovered the following inventions (1) to (10). (1) An absorption control agent for an active ingredient, comprising an ionic liquid. (2) The absorption control agent according to (1), wherein the active ingredient satisfies the following formula 1. (24-hour cumulative permeation amount of active ingredient through hairless mouse skin with an electrical resistance of 2.5 kΩ or less) ÷ (24-hour cumulative permeation amount through hairless mouse skin with an electrical resistance of 7.0 kΩ or more) ≧5 Formula 1 (3) A pharmaceutical composition comprising the absorption control agent according to (1) or (2) and an active ingredient. (4) The pharmaceutical composition according to (3), which satisfies the following formula 2: (24-hour cumulative permeation amount of the active ingredient through hairless mouse skin with an electrical resistance of 1.3 kΩ or more and less than 4.0 kΩ) ÷ (24-hour cumulative permeation amount of the active ingredient through hairless mouse skin with an electrical resistance of 7.0 kΩ or more and 10.0 kΩ or less) ≦ 5 ... Formula 2 (5) The pharmaceutical composition according to (3) or (4), wherein the absorption controller is an ionic liquid having an anion represented by the following general formula (I) or (II), and the active ingredient is a basic drug selected from the group consisting of skeletal muscle relaxants, antiepileptic drugs, drugs for treating Parkinson's disease, antipsychotic drugs, drugs for treating dementia, drugs for treating attention deficit hyperactivity disorder, Janus kinase inhibitors, drugs for treating migraine, and phosphodiesterase 4 inhibitors. [ka] (In formula (II), R 1 represents a hydrogen atom or an acyl group, R 2 represents an alkyl group which may be substituted with a halogen atom, a halogen atom, a sulfo group, an aryl group, or an alkoxy group. (6) The pharmaceutical composition according to any one of (3) to (5), which is an external preparation. (7) A quasi-drug or cosmetic comprising the absorption regulator described in (1) or (2) and an active ingredient. (8) The quasi-drug or cosmetic according to (7), which satisfies the following formula 2: (24-hour cumulative permeation amount of the active ingredient through hairless mouse skin with an electrical resistance of 1.3 kΩ or more and less than 4.0 kΩ) ÷ (24-hour cumulative permeation amount of the active ingredient through hairless mouse skin with an electrical resistance of 7.0 kΩ or more and 10.0 kΩ or less) ≦ 5 ... Formula 2 (9) The quasi-drug or cosmetic according to (7) or (8), wherein the absorption control agent is an ionic liquid having an anion represented by the following general formula (I) or (II), and the active ingredient is selected from the group consisting of glutathione, L-cysteine, tryptophan, histidine, nicotinamide, hydroxyproline, serine, arginine, alanine, γ-aminobutyric acid, and derivatives thereof, and pharmacologically acceptable salts thereof. [ka] (In formula (II), R 1 represents a hydrogen atom or an acyl group, R 2 represents an alkyl group which may be substituted with a halogen atom, a halogen atom, a sulfo group, an aryl group, or an alkoxy group. (10) A therapeutic or preventive agent for a disease accompanied by stratum corneum damage, comprising the absorption regulator according to (1) or (2) and an active ingredient. Effect of the Invention
[0013] According to the present invention, the absorption amount of active ingredients used in medicines, quasi-drugs, and cosmetics can be controlled within a certain range regardless of the strength of the barrier function of biological membranes such as the skin and mucous membranes by changing the active ingredient into a state that is less susceptible to the effect of the skin's barrier function through the interaction of the ionic liquid with the active ingredient. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] The absorption controller of the present invention is capable of controlling the amount of an active ingredient absorbed within a certain range, regardless of the strength of the barrier function of the biomembrane, in the absorption of the active ingredient through a biomembrane such as the skin or mucous membrane. On the other hand, an absorption enhancer is intended to promote the absorption of an active ingredient, and has a different function from the absorption controller of the present invention.
[0015] The absorption control agent of the present invention is characterized by containing an ionic liquid. It is believed that the ionic liquid interacts with the active ingredient, changing the active ingredient into a state that is less susceptible to the barrier function of the skin, thereby controlling the amount of permeation into the skin. In addition, the absorption amount can be controlled by the same action on lipid-soluble biological membranes such as mucous membranes present in the digestive tract and nose, just like the skin. In the case of an absorption enhancer, since it acts on the skin and changes its structure, it is believed that the mechanism of action is different from that of an absorption control agent.
[0016] Due to the differences in the above-mentioned mechanisms, for example, in the case of transdermal administration, absorption enhancers are effective mainly when administered to patients with normal skin barrier function, whereas the absorption control agent of the present invention can keep the absorption amount of the active ingredient within a certain range in both patients with reduced and normal skin barrier function, and therefore can be preferably used when administered to elderly people and children who are considered to have low skin barrier function, or patients with skin diseases such as atopic dermatitis whose skin barrier function is prone to fluctuations.
[0017] An ionic liquid is defined as a salt that has a melting point below 100°C and in which at least one of the cations or anions is organic (Science of Ionic Liquids - Challenges to a New Generation of Liquids, page 7).
[0018] Examples of cations constituting the ionic liquid of the present invention include those having a nitrogen atom as the ion center, those having a phosphorus atom as the ion center, those having a sulfur atom as the ion center, and those having a nitrogen atom and a sulfur atom as the ion center.
[0019] Examples of the cation having a nitrogen atom as the ion center include an imidazolium ion, an ammonium ion, a pyridinium ion, a quinolinium ion, a pyrrolidinium ion, a piperidinium ion, a piperazinium ion, a morpholinium ion, a pyridazinium ion, a pyrimidinium ion, a pyrazinium ion, a pyrazolium ion, a thiazolium ion, an oxazolium ion, a triazolium ion, a guanidium ion, and a 4-aza-1-azonia-bicyclo-[2,2,2]octanium ion, etc. In addition, these cations may have a substituent such as an alkyl group at any position, and the number of the substituents may be multiple.
[0020] As the cation having a nitrogen atom as the ion center, an imidazolium ion, an ammonium ion, a pyridinium ion, a pyrrolidinium ion, or a piperidinium ion is preferred because of their ease of availability and structural transformation.
[0021] Examples of imidazolium ions include 1-methylimidazolium ion, 1-ethylimidazolium ion, 1-propylimidazolium ion, 1-butylimidazolium ion, 1-butyl-3-methylimidazolium ion, 1-ethyl-3-methylimidazolium ion, 1-allyl-3-methylimidazolium ion, 1,3-diallylimidazolium ion, 1-benzyl-3-methylimidazolium ion, 1-methyl-3-octylimidazolium ion, 1-ethyl-2,3-dimethylimidazolium ion, 1-butyl-2,3-dimethylimidazolium ion, 1,2-dimethyl-3-propylimidazolium ion, and 1-cyanopropyl-3-methylimidazolium. ion, 1,3-biscyanomethylimidazolium ion, 1,3-bis(3-cyanopropyl)imidazolium ion, 1-(2-hydroxyethyl)-3-methylimidazolium ion, 1-methoxyethyl-3-methylimidazolium ion, 1-[2-(2-methoxyethoxy)-ethyl]-3-methylimidazolium ion, 1,3-diethoxyimidazolium ion, 1,3-dimethoxyimidazolium ion, 1,3-dihydroxyimidazolium ion, 1-methyl-3-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctylimidazolium ion, or 1-methyl-3-[(triethoxysilyl)propyl]imidazolium ion.
[0022] Examples of the ammonium ion include tetraalkylammonium ions such as tetramethylammonium ion, tetraethylammonium ion, tetrapropylammonium ion, tetrabutylammonium ion, tetrahexylammonium ion, and trihexyltetradecylammonium ion; (2-hydroxyethyl)trimethylammonium ion, N,N-diethyl-N-(2-methoxyethyl)-N-methylammonium ion, tris(2-hydroxyethyl)methylammonium ion, trimethyl(1H,1H,2H,2H-heptadecafluorodecyl)ammonium ion, trimethyl-(4-vinylbenzyl)ammonium ion, tributyl-(4-vinylbenzyl)ammonium ion, 2-(methacryloyloxy)ethyltrimethylammonium ion, benzyldimethyl(octyl)ammonium ion, and N,N-dimethyl-N-(2-phenoxyethyl)-1-dodecylammonium ion.
[0023] Examples of pyridinium ions include a 1-ethylpyridinium ion, a 1-butylpyridinium ion, a 1-(3-hydroxypropyl)pyridinium ion, a 1-ethyl-3-methylpyridinium ion, a 1-butyl-3-methylpyridinium ion, a 1-butyl-4-methylpyridinium ion, and a 1-(3-cyanopropyl)pyridinium ion.
[0024] Examples of pyrrolidinium ions include 1-methyl-1-propylpyrrolidinium ion, 1-butyl-1-methylpyrrolidinium ion, 1-(2-hydroxyethyl)-1-methylpyrrolidinium ion, and 1-ethyl-1-methylpyrrolidinium ion.
[0025] Examples of piperidinium ions include 1-methyl-1-propylpiperidinium ion, 1-butyl-1-methylpiperidinium ion, 1-(2-hydroxyethyl)-1-methylpiperidinium ion, and 1-ethyl-1-methylpiperidinium ion.
[0026] Cations having a phosphorus atom as the ionic center are generally called phosphonium ions, and examples thereof include tetraalkylphosphonium ions such as tetrapropylphosphonium ion, tetrabutylphosphonium ion, tetrahexylphosphonium ion, trihexyltetradecylphosphonium ion, triphenylmethylphosphonium ion, triisobutylmethylphosphonium ion, triethylmethylphosphonium ion, tributylmethylphosphonium ion, and tributylhexadecylphosphonium ion; (2-cyanoethyl)triethylphosphonium ion, (3-chloropropyl)trioctylphosphonium ion, tributyl(4-vinylbenzyl)phosphonium ion, and 3-(triphenylphosphonio)propane-1-sulfonic acid ion.
[0027] A cation having a sulfur atom as the ionic center is generally called a sulfonium ion, and examples thereof include a triethylsulfonium ion, a tributylsulfonium ion, a 1-ethyltetrahydrothiophenium ion, and a 1-butyltetrahydrothiophenium ion.
[0028] From the viewpoint of exhibiting an absorption control effect for various active ingredients, the cation of the ionic liquid contained in the absorption control agent of the present invention is preferably an ammonium ion or a phosphonium ion, and more preferably a tetraalkylammonium ion or a tetraalkylphosphonium ion.
[0029] The total carbon number of the four alkyl groups of the cation is preferably 13 to 35, more preferably 13 to 25. Examples of the tetraalkylammonium ion include tetrabutylammonium ion, tetrapentylammonium ion, tetrahexylammonium ion, tetraheptylammonium ion, tetraoctylammonium ion, and trioctylmethylammonium ion. Examples of the tetraalkylphosphonium ion include tetrabutylphosphonium ion, tetrapentylphosphonium ion, tetrahexylphosphonium ion, tetraoctylphosphonium ion, tributylhexylphosphonium ion, tributylheptylphosphonium ion, tributyloctylphosphonium ion, tributyldodecylphosphonium ion, tributyltridecylphosphonium ion, tributylpentadecylphosphonium ion, tributylhexadecylphosphonium ion, and trihexyltetradecylphosphonium ion. The four alkyl groups of the tetraalkylammonium ion or tetraalkylphosphonium ion may be the same or different.
[0030] Examples of anions in ionic liquids include, but are not limited to, halide ions, imide ions such as bis(trifluoromethylsulfonyl)imide, carboxylate ions, sulfonate ions, phosphate ions, phosphonate ions, phosphinate ions, amino acid ions, etc. Furthermore, these anions may have a substituent, typically an alkyl group or an aryl group, at any position, and the number of substituents may be multiple.
[0031] In order to exhibit an absorption control effect for various active ingredients, the anion of the ionic liquid contained in the absorption control agent of the present invention is preferably a carboxylate ion (carboxylic acid ion), more preferably an aromatic carboxylate ion, and even more preferably an anion derived from salicylic acid or a salicylic acid derivative.
[0032] Examples of aromatic carboxylate ions include substituted or unsubstituted benzoate ions, for example, benzoate ions substituted with an alkyl group which may be substituted with a benzoate ion, a toluate ion, a trifluoromethylbenzoate ion, or the like; halogenated benzoate ions such as a fluorobenzoate ion, a chlorobenzoate ion, a bromobenzoate ion, or an iodobenzoate ion; acylated benzoate ions such as a formylbenzoate ion or an acetylbenzoate ion; alkoxylated benzoate ions or sulfobenzoate ions such as a hydroxybenzoate ion, an aminobenzoate ion, or a methoxybenzoate ion; and substituted or unsubstituted polycyclic aromatic carboxylate ions, for example, a naphthalenecarboxylate ion or an anthracenecarboxylate ion.
[0033] As long as the combination results in a temperature-responsive ionic liquid, the position of the substituent on the aromatic carboxylate ion may be any position, and there is no particular limitation on the number or type of the substituent. When a hydroxyl group, an amino group, or the like is contained as a substituent, the hydroxyl group, the amino group, or the like may be further substituted with an acyl group, or the like.
[0034] Examples of the salicylic acid derivative in the anion derived from salicylic acid or a salicylic acid derivative include a compound having a substituent on the benzene ring of salicylic acid and a compound having a substituent on a phenolic hydroxyl group. In one embodiment, the anion constituting the ionic liquid is, for example, an anion represented by the following general formula (I) or general formula (II). [ka] (In formula (II), R 1 represents a hydrogen atom or an acyl group, R 2 represents an alkyl group which may be substituted with a halogen atom, a halogen atom, a sulfo group, an aryl group, or an alkoxy group.
[0035] The ionic liquid contained in the absorption control agent of the present invention can be synthesized according to a general synthesis method of ionic liquid. For example, when the ionic liquid is an ammonium salt, (1) a method (anion exchange method) in which an ammonium salt obtained by reacting an amine with an alkyl halide compound or the like is subjected to anion exchange using a metal salt and purified to obtain the desired ammonium salt, or (2) a method (neutralization method) in which an amine or ammonium hydroxide is directly reacted with an acid and neutralized to obtain the desired ammonium salt, can be mentioned. When the ionic liquid is a phosphonium salt, it can be synthesized by either the above-mentioned anion exchange method or neutralization method. In the case of the neutralization method, the desired phosphonium salt can be obtained by directly reacting a phosphonium hydroxide with an acid and neutralizing it.
[0036] In the synthesis of the ionic liquid used in the present invention, one kind of cation and two or more kinds of anions, two or more kinds of cations and one kind of anion, or two or more kinds of cations and two or more kinds of anions may be used. For example, an ionic liquid containing one kind of cation and two kinds of anions can be obtained by mixing salicylic acid and 4-methoxysalicylic acid as anions in any ratio so that the total amount of both is 1 mole per mole of tetrabutylphosphonium hydroxide as a cation.
[0037] The ionic liquid used in the present invention is preferably a temperature-responsive ionic liquid. The temperature-responsive ionic liquid refers to an ionic liquid that exhibits temperature responsiveness. The temperature-responsive ionic liquid has a suitable balance of hydrophilicity and hydrophobicity, and can function as an absorption control agent for a wide range of active ingredients.
[0038] Here, temperature responsiveness refers to a property of changing shape and / or properties in response to a change in temperature (heat). Examples of the temperature responsiveness of an ionic liquid include a volume change such as expansion and contraction, and a change in hydrophobicity such as the lower critical solution temperature (hereinafter referred to as "LCST") or upper critical solution temperature (hereinafter referred to as "UCST").
[0039] Among the temperature-responsive ionic liquids, from the viewpoint of controlling the amount of drug permeation, it is preferable that the temperature-responsive ionic liquid has an LCST, and the LCST is preferably 40° C. or lower.
[0040] Examples of the temperature-responsive ionic liquid include temperature-responsive ionic liquids containing an anion represented by the above general formula (I) or general formula (II) and an ammonium ion (e.g., a tetraalkylammonium ion) or a phosphonium ion (e.g., a tetraalkylphosphonium ion).
[0041] Examples of the temperature-responsive ionic liquid include tetrabutylammonium salicylate, tetrabutylammonium 4-(trifluoromethyl)salicylate, tetrabutylphosphonium salicylate, tetrabutylphosphonium 4-(trifluoromethyl)salicylate, tetrabutylphosphonium acetylsalicylate, tetrabutylphosphonium 5-bromosalicylate, tetrabutylphosphonium 4-chlorosalicylate, tetrabutylphosphonium 5-chlorosalicylate, tetrabutylphosphonium 5-iodosalicylate, and tetrabutylphosphonium acetylsalicylate. Examples of the phosphonium salt include 3-methylsalicylate, 4-methylsalicylate, 5-sulfosalicylate, 4-methoxysalicylate, 4-fluorosalicylate, 6-fluorosalicylate, 4-methoxysalicylate, 4-fluorosalicylate, 6-fluorosalicylate, and 3-phenylsalicylate.
[0042] The absorption control agent of the present invention can be used as a pharmaceutical composition, a quasi-drug, or a cosmetic containing an active ingredient. The active ingredient is not particularly limited, and can be appropriately selected from known active ingredients.
[0043] More preferably, the active ingredient is a basic compound, an amino acid, or a salt thereof. The basic compound is not particularly limited as long as it is a compound that exhibits basicity, such as amines. These compounds are preferred because they tend to interact with the ionic liquid and therefore tend to fully exert their absorption control effect.
[0044] Specific examples of drugs used as an active ingredient in the absorption control agent of the present invention include steroidal anti-inflammatory drugs such as prednisolone, dexamethasone, hydrocortisone, fluocinolone acetonide, betamethasone valerate, betamethasone dipropionate, clobetasone butyrate, and prednisolone succinate; and non-steroidal anti-inflammatory drugs such as indomethacin, diclofenac, ibuprofen, ketoprofen, flufenamic acid, ketorolac, flurbiprofen, felbinac, suprofen, pranoprofen, tiaprofen, and loxoprofen. antiallergic agents and their ester derivatives, such as tranilast, azelastine, ketotifen, ibudilast, oxatomide or emedastine, antihistamines such as diphenhydramine, chlorpheniramine, promethazine or tripelennamine, central nervous system acting drugs such as chlorpromazine, nitrazepam, diazepam, phenobarbital or reserpine, hormones such as insulin, testosterone, norethisterone, methyltestosterone, progesterone or estradiol, clonidine, reserpine or sulfate Antihypertensives such as guanethidine, cardiac stimulants such as digitoxin or digoxin, antiarrhythmics such as propranolol hydrochloride, procainamide hydrochloride, ajmaline, pindolol or tulobuterol hydrochloride, coronary vasodilators such as nitroglycerin, isosorbide dinitrate, papaverine hydrochloride or nifedipine, local anesthetics such as lidocaine, benzocaine, procaine hydrochloride or tetracaine, analgesics such as morphine, aspirin, codeine, tramadol, pregabalin, mirogabalin, acetanilide, aminopyrine or etodolac, eperisone , skeletal muscle relaxants such as tizanidine, tolperisone, inaperisone, or pridinol mesylate; antifungal agents such as acetophenylamine, nitrofurazone, pentamycin, naphthiomate, miconazole, omoconazole, clotrimazole, butenafine hydrochloride, or bifonazole; anticancer agents such as 5-fluorouracil, busulfan, actinomycin, bleomycin, or mitomycin; urinary disorder agents such as terodiline hydrochloride or oxybutynin hydrochloride; antiepileptic agents such as nitrazepam or meprobamate; rotigotine, ropinirole,Parkinson's disease treatment drugs such as chlorzoxazone or levodopa, antipsychotic drugs such as venlafaxine or blonanserin, dementia treatment drugs such as memantine, donepezil or rivastigmine, attention deficit hyperactivity disorder treatment drugs such as methylphenidate, amphetamine, modafinil, atomoxetine or guanfacine, Janus kinase inhibitors such as baricitinib, tofacitinib, ruxolitinib, peficitinib, filgotinib, delgocitinib or abrocitinib, sumatriptan, zolmitriptan, eletriptan, Examples of such drugs include migraine drugs such as rizatriptan or naratriptan, phosphodiesterase 4 inhibitors such as difamilast, roflumilast or apremilast, smoking cessation aids such as nicotine, vitamins or prostaglandins, and among these, a basic drug selected from the group consisting of skeletal muscle relaxants, antiepileptic drugs, Parkinson's disease drugs, antipsychotic drugs, dementia drugs, attention deficit hyperactivity drugs, Janus kinase inhibitors, migraine drugs, and phosphodiesterase 4 inhibitors is preferable because it can be suitably used for external preparations. Furthermore, these drugs may be their pharmacologically acceptable salts or solvates thereof.
[0045] Specific active ingredients used in quasi-drugs or cosmetics include, for example, arbutin, L-ascorbic acid, hydroquinone, glutathione, pantothenic acid, tranexamic acid, kojic acid, L-cysteine, ellagic acid, rucinol, resorcin, astaxanthin and derivatives thereof, rutin, cholesterol and derivatives thereof, tryptophan, histidine, flavonoids such as quercetin and quercitrin, catechin and derivatives thereof, gallic acid and derivatives thereof, kinetin, α-lipoic acid, erythorbic acid and derivatives thereof, thiotaurine, urea, nicotinic acid, nicotinic acid alpha amide, hydroxyproline, serine, glutamic acid, arginine, alanine, minoxidil, D-glucosamine, N-acetyl-D-glucosamine, hyaluronic acid, raffinose, azelaic acid, γ-aminobutyric acid, allantoin, L-carnitine or biotin, and among these, it is preferable to select from the group consisting of amines or amino acids, such as glutathione, L-cysteine, tryptophan, histidine, nicotinamide, hydroxyproline, serine, arginine, alanine, γ-aminobutyric acid and their derivatives and their pharmacologically acceptable salts.In addition, these active ingredients may be their solvates.
[0046] Here, examples of pharmacologically acceptable salts include salts with inorganic acids or salts with organic acids. Examples of salts with inorganic acids include hydrochloride, sulfate, nitrate, hydrobromide, hydroiodide, or phosphate. Examples of salts with organic acids include oxalate, malonate, citrate, fumarate, lactate, malate, succinate, tartrate, acetate, trifluoroacetate, maleate, gluconate, benzoate, ascorbate, glutarate, mandelate, phthalate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, aspartate, glutamate, or cinnamate. Examples of solvates include hydrates.
[0047] The active ingredient is preferably an active ingredient that satisfies the following formula 1: (24-hour cumulative permeation amount of active ingredient through mouse skin with an electrical resistance of 2.5 kΩ or less) ÷ (24-hour cumulative permeation amount through mouse skin with an electrical resistance of 7.0 kΩ or more) ≧5 Formula 1
[0048] Here, the electric resistance value is an index of the barrier function of the skin, and the lower the electric resistance value, the lower the barrier function of the skin. Therefore, since the active ingredient satisfying formula 1 has a property of being difficult to permeate through skin with a high barrier function and being easy to permeate through skin with a low barrier function, the active ingredient requires the absorption control agent of the present invention in order to keep the permeation amount constant regardless of the skin condition.
[0049] The electrical resistance can be measured as follows: Thawed hairless mouse skin (product name: Labo Skin, obtained from Hoshino Laboratory Animal Breeding Center) is placed in a vertical Franz cell, and then the receiver cell is filled with phosphate buffered saline (Ca, Mg free, hereafter referred to as PBS(-)), and the donor cell is also filled with PBS(-). After leaving it to stand for 50 minutes, the electrical resistance of the mouse skin can be measured using a stratum corneum impedance meter (AS-TZ1, manufactured by Nippon Ash Co., Ltd.).
[0050] The 24-hour cumulative permeation amount can be measured by the following method. The hairless mouse skin (trade name: Labo Skin) that had been immersed in a vertical Franz cell was set with the stratum corneum side facing up. The receiver cell side was filled with phosphate buffered saline (PBS(-)) so that air would not enter. After that, the donor cell was placed on the skin and clamped, and then the donor cell was filled with PBS(-) to start hydration of the hairless mouse skin, and after 1 hour, the PBS(-) in the donor cell was removed. Then, a composition containing an active ingredient was added to the donor cell to start the permeation test. 500 μL of the receiver solution was sampled at 1, 2, 3, 4, 5, 6, 7, 8, and 24 hours after the start of the test, and the same amount (500 μL) of PBS(-) was replenished. The concentration of the active ingredient in the sampled solution was measured, and the value was substituted into Equation 3 to calculate the 24-hour cumulative permeation amount of the active ingredient.
number
[0051] Since the pharmaceutical composition containing the absorption control agent of the present invention can control the permeability of the drug not only to the skin but also to the mucosa, commonly known administration routes such as oral administration, transmucosal administration such as nasal administration, and parenteral administration such as pulmonary administration or transdermal administration can be used, and transmucosal administration or transdermal administration is preferred.
[0052] When a pharmaceutical composition containing the absorption control agent of the present invention is orally administered, examples of the dosage form include tablets (including sugar-coated tablets and film-coated tablets), pills, granules, powders, capsules (including soft capsules and microcapsules), syrups, emulsions, and suspensions.
[0053] Preparations for oral administration can be prepared according to known manufacturing methods commonly used in the field of formulations, and can be produced by appropriately incorporating pharmacologically acceptable additives commonly used in the field of formulations, such as excipients, binders, lubricants, disintegrants, sweeteners, surfactants, suspending agents, or emulsifiers.
[0054] When the pharmaceutical composition containing the absorption control agent of the present invention is administered parenterally, examples of the dosage form include nasal preparations, eye drops, injections, infusions, drops, topical preparations, and suppositories. The pharmaceutical composition containing the absorption control agent of the present invention is preferably a topical preparation, which is a non-invasive administration method, because it can control the absorption of the active ingredient regardless of the skin condition.
[0055] The topical preparation may be in any conventionally used dosage form, such as an ointment, cream, gel, gel-like cream, lotion, spray, cataplasm, tape, or reservoir-type patch.
[0056] The preparation of the above-mentioned external preparation can be carried out according to a known manufacturing method generally used in the pharmaceutical field, and can be produced by appropriately adding pharmacologically acceptable additives generally used in the pharmaceutical field. Representative dosage forms, cataplasms and tapes, are described below, but are not limited thereto.
[0057] In preparing the cataplasm, for example, a water-soluble polymer or a polyhydric alcohol can be used as a pharmacologically acceptable additive.
[0058] Examples of water-soluble polymers include gelatin, casein, pullulan, dextran, sodium alginate, soluble starch, carboxystarch, dextrin, carboxymethylcellulose, sodium carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, polyvinyl alcohol, polyethylene oxide, polyacrylic acid, polyacrylamide, sodium polyacrylate, polyvinylpyrrolidone, carboxyvinyl polymer, polyvinyl ether, methoxyethylene-maleic anhydride copolymer, isobutylene-maleic anhydride copolymer, N-vinylacetamide, and copolymers of N-vinylacetamide and acrylic acid or acrylate salts.
[0059] Examples of polyhydric alcohols include polyethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, isobutylene glycol, glycerin, diglycerin, and sorbitol.
[0060] In preparing the tape preparation, for example, an adhesive base or a tackifier can be used as a pharmacologically acceptable additive.
[0061] The adhesive base can be appropriately selected from known adhesives taking into consideration skin safety, medicinal ingredient release, adhesion to the skin, etc., and examples thereof include acrylic adhesives, rubber adhesives, and silicone adhesives.
[0062] Examples of the acrylic adhesive include homopolymers or copolymers of (meth)acrylic acid alkyl esters, and copolymers of (meth)acrylic acid alkyl esters and other functional monomers.
[0063] Examples of rubber-based adhesives include natural rubber, synthetic isoprene rubber, polyisobutylene, polyvinyl ether, polyurethane, polyisoprene, polybutadiene, styrene-butadiene copolymer, styrene-isoprene copolymer, and styrene-isoprene-styrene block copolymer.
[0064] Examples of silicone-based adhesives include polyorganosiloxane and polydimethylsiloxane.
[0065] Examples of tackifiers include rosin-based rosin or hydrogenated, disproportionated, polymerized or esterified rosin derivatives, terpene resins such as α-pinene and β-pinene, terpene-phenol resins, aliphatic, aromatic, alicyclic or copolymerized petroleum resins, alkyl-phenyl resins, and xylene resins.
[0066] The quasi-drugs and cosmetics of the present invention have an absorption control agent and an active ingredient. Here, the quasi-drugs and cosmetics can be produced according to a known production method. In addition to the active ingredient and the absorption control agent, the quasi-drugs and cosmetics can be appropriately blended with powder components, oily components, UV absorbers, various aqueous solvents, sequestering agents, monosaccharides, oligosaccharides, amino acids, organic amines, polymer emulsions, alcohols, pH adjusters, dispersants, antioxidants, fragrances, preservatives, stabilizers, etc. as necessary.
[0067] The above-mentioned quasi-drugs and cosmetics can be in any conventionally used dosage form, such as an ointment, cream, gel, gel-like cream, lotion, spray, patch, tape, etc. Specific examples of the products include skin lotions, milky lotions, beauty essences, and skin care creams.
[0068] The pharmaceutical composition, quasi-drug or cosmetic of the present invention contains an absorption controller and an active ingredient, and can control the permeation amount of the active ingredient to a constant level regardless of the strength of the skin's barrier function. The strength of the skin's barrier function can be evaluated by measuring the skin's electrical resistance using a stratum corneum impedance meter, and it can be determined that the lower the skin's electrical resistance, the lower the skin's barrier function.
[0069] In one embodiment, the pharmaceutical composition, quasi-drug, or cosmetic satisfies the following formula 2. (24-hour cumulative permeation amount of the active ingredient through hairless mouse skin with an electrical resistance of 1.3 kΩ or more and less than 4.0 kΩ) ÷ (24-hour cumulative permeation amount of the active ingredient through hairless mouse skin with an electrical resistance of 7.0 kΩ or more and 10.0 kΩ or less) ≦ 5 ... Formula 2
[0070] When the above pharmaceutical composition, quasi-drug, or cosmetic satisfies formula 2, the amount of permeation can be made constant in both skin with low and skin with high skin barrier function, and therefore the composition can be suitably used as an external preparation for skin, or a quasi-drug or cosmetic to be applied to the skin.
[0071] The pharmaceutical composition can be used as a therapeutic or preventive agent for diseases accompanied by stratum corneum damage. The stratum corneum is located at the top layer of the skin and functions as the largest barrier in the skin. For example, in the treatment of diseases accompanied by stratum corneum damage, such as atopic dermatitis, the amount of active ingredient that permeates may be excessive in the early stages of treatment due to a decrease in the skin barrier function, while when the treatment progresses and the skin barrier function is normalized, there is a problem that a sufficient amount of active ingredient does not permeate the skin, resulting in insufficient therapeutic effect. The therapeutic composition containing the absorption control agent of the present invention can control the amount of active ingredient that permeates to a constant level regardless of the skin barrier function, and therefore can solve the above-mentioned condition of overdosing or underdosing of active ingredient depending on the skin condition. EXAMPLES
[0072] The present invention will be described in detail below with reference to examples, but the present invention is not limited thereto. In addition, for compounds used in the synthesis of the compounds in the examples and comparative examples for which no synthesis method is described, commercially available compounds were used. Unless otherwise specified, commercially available reagents were used in the reactions without purification. First, the measurement and test methods are shown below.
[0073] (Synthesis Example 1) Synthesis of ionic liquid: As the cationic component, 6.91 g (10 mmol) of a 40% by mass aqueous solution of tetrabutylphosphonium hydroxide and 1.38 g (10 mmol) of salicylic acid were weighed as the anionic component and placed in a glass vial. The mixture was stirred at room temperature for 2 hours, and the reaction was terminated after confirming that the salicylic acid had completely dissolved, thereby quantitatively obtaining a mixed solution of tetrabutylphosphonium salicylate and water (hereinafter referred to as "Sample 1"). Sample 1 was diluted and used for the permeation test of the active ingredient.
[0074] (Example 1) Confirmation of the effect of an absorption regulator in a skin permeation test of sumatriptan succinate using hairless mouse skin: The thermostatic water bath was set to 32°C, and the thermostatic water bath and the Franz cells were connected in series with a silicon tube so that the receiver solution was kept at a constant temperature. 2 After thawing at room temperature, hairless mouse skin (trade name: Labo Skin) cut to the size of the cell was placed in a receiver cell with the stratum corneum side facing up. The receiver cell side was filled with PBS(-) so as not to let air in. Then, the donor cell was placed on the skin and clamped, and 1 mL of PBS(-) was filled into the donor cell to start hydration of the hairless mouse skin. 50 minutes after the start of hydration, the electrical resistance of the skin used in the test was measured using a stratum corneum impedance meter (AS-TZ1, manufactured by Nippon Ash Co., Ltd.). After 1 hour from the start of hydration, the PBS(-) in the donor cell was removed, and 500 μL of a 5% aqueous solution of ionic liquid containing 1 mg / mL sumatriptan succinate was added to the donor cell as a test solution to start the permeation test. 500 μL of the receiver solution was sampled at 1, 2, 3, 4, 5, 6, 7, 8, and 24 hours after the start of the test, and the same amount (500 μL) of PBS(-) was added. The concentration of the active ingredient in the sampled receiver fluid was measured using LC / MS / MS, and the value was substituted into Equation 3 to calculate the 24-hour cumulative permeation amount of the active ingredient.
number
[0075] The ionic liquid aqueous solution used was prepared by diluting Sample 1 to 5%.
[0076] (LC / MS / MS analysis conditions) Liquid chromatograph (LC): Prominence UFLC (Shimadzu Corporation) Mass spectrometer (MS / MS): QTRAP (registered trademark) 3200 (manufactured by Sciex Corporation) or LC: Exion LC (Sciex) MS / MS: TripleQuad (registered trademark) 7500 (manufactured by Sciex) Column: CAPCELL PAK C18 MGIII, 5 μm, 2.0 mm ID × 50 mm (Osaka Soda Co., Ltd.) Mobile phase: A: 0.1% by weight formic acid aqueous solution B: 0.1% by weight formic acid-containing acetonitrile Gradient conditions: A:B = 95:5 → 10:90 Column temperature: 40℃ Flow rate: 0.5mL / min Measurement time: 5 minutes Sample injection volume: 10 μL (for Prominence UFLC) 1μL (for Exion LC)
[0077] (Comparative Example 1) Permeation test of sumatriptan succinate using hairless mouse skin without using an absorption regulator: The same procedure as in Example 1 was carried out except that the test solution was an aqueous solution of 1 mg / mL sumatriptan succinate.
[0078] (Example 2, Comparative Example 2) Permeation test of memantine hydrochloride using hairless mouse skin: In Example 2, the test solution was changed to a 5% ionic liquid aqueous solution containing 1 mg / mL memantine hydrochloride, and in Comparative Example 2, the test solution was changed to a 1 mg / mL aqueous solution of memantine hydrochloride. In Example 2 and Comparative Example 2, the tests were performed in the same manner as in Example 1, except that the temperature of the thermostatic water bath was set to 37°C.
[0079] The LC / MS / MS analysis conditions were the same as those for sumatriptan succinate.
[0080] (Example 3, Comparative Example 3) Permeation test of venlafaxine hydrochloride using hairless mouse skin: In Example 3, the test solution was changed to a 5% ionic liquid aqueous solution containing 1 mg / mL venlafaxine hydrochloride, and in Comparative Example 2, the test solution was changed to a 1 mg / mL aqueous solution of venlafaxine hydrochloride. In Example 3 and Comparative Example 3, the tests were performed in the same manner as in Example 1, except that the temperature of the thermostatic water bath was set to 37°C.
[0081] The LC / MS / MS analysis conditions were the same as those for sumatriptan succinate.
[0082] [Table 1]
[0083] In Examples 1 to 3, since the absorption control agent of the present invention was used, the amount of permeation of the active ingredient remained within a certain range even if the electrical resistance value of the skin fluctuated, and it was confirmed that the ionic liquid functions as an absorption control agent. On the other hand, in Comparative Examples 1 to 3, it was found that the amount of permeation of the active ingredient fluctuated greatly depending on the fluctuation of the electrical resistance value of the skin.
[0084] Specifically, the variation ratio of the permeation amount of the active ingredient when skin with low electrical resistance is used to the permeation amount of the active ingredient when skin with high electrical resistance is used was 0.82 times, 1.1 times, and 1.0 times, respectively, in Examples 1 to 3, while it was 33 times, 11 times, and 2 times in Comparative Examples 1 to 3. From these results, it was found that by using the absorption controller of the present invention, the permeation amount of the active ingredient can be controlled even if the strength of the electrical resistance value of the skin, that is, the strength of the barrier function, varies.
[0085] (Example 4, Comparative Example 4) Permeation test of sodium fluorescein using hairless mouse skin: In Example 4, the test solution was changed to a 5% ionic liquid aqueous solution containing 1 mg / mL sodium fluorescein, and in Comparative Example 4, the test solution was changed to a 1 mg / mL aqueous solution of sodium fluorescein, but other than that, tests were performed in the same manner as in Example 1. The amount of sodium fluorescein permeated was measured using a fluorescent plate reader.
[0086] [Table 2]
[0087] The variation factor of the amount of active ingredient permeation when skin with a low electrical resistance was used relative to the amount of active ingredient permeation when skin with a high electrical resistance was used was 10 times in Example 4, while it was 68 times in Comparative Example 4, indicating that the absorption control agent of the present invention also exhibits the function of controlling the amount of drug permeation for sodium fluorescein. [Industrial Applicability]
[0088] The absorption control agent of the present invention can control the permeation amount of an active ingredient to a constant level regardless of the barrier function of the skin or mucous membrane, and can therefore be used as medicines such as external preparations, quasi-drugs, and cosmetics.
Claims
1. An absorption control agent for an active ingredient, comprising an ionic liquid.
2. The absorption control agent according to claim 1 , wherein the active ingredient satisfies the following formula 1: (24-hour cumulative permeation amount of an active ingredient through hairless mouse skin with an electrical resistance value of 2.5 kΩ or less) ÷ (24-hour cumulative permeation amount through hairless mouse skin with an electrical resistance value of 7.0 kΩ or more) ≧5 ... Formula 1
3. A pharmaceutical composition comprising the absorption control agent according to claim 1 or 2 and an active ingredient.
4. The pharmaceutical composition according to claim 3, which satisfies the following formula 2: (24-hour cumulative permeation amount of the active ingredient through hairless mouse skin having an electrical resistance value of 1.3 kΩ or more and less than 4.0 kΩ) ÷ (24-hour cumulative permeation amount of the active ingredient through hairless mouse skin having an electrical resistance value of 7.0 kΩ or more and 10.0 kΩ or less) ≦ 5 ... formula 2
5. The absorption control agent is an ionic liquid having an anion represented by the following general formula (I) or (II):
5. The pharmaceutical composition according to claim 3 or 4, wherein the active ingredient is a basic drug selected from the group consisting of skeletal muscle relaxants, antiepileptic drugs, drugs for treating Parkinson's disease, antipsychotic drugs, drugs for treating dementia, drugs for treating attention deficit hyperactivity disorders, Janus kinase inhibitors, drugs for treating migraine headaches, and phosphodiesterase 4 inhibitors. 【Chemistry 1】 (In formula (II), R 1 represents a hydrogen atom or an acyl group; R 2 represents an alkyl group which may be substituted with a halogen atom, a halogen atom, a sulfo group, an aryl group, or an alkoxy group.
6. The pharmaceutical composition according to any one of claims 3 to 5, which is an external preparation.
7. A quasi-drug or cosmetic comprising the absorption control agent according to claim 1 or 2 and an active ingredient.
8. The quasi-drug or cosmetic according to claim 7, which satisfies the following formula 2: (24-hour cumulative permeation amount of the active ingredient through hairless mouse skin having an electrical resistance value of 1.3 kΩ or more and less than 4.0 kΩ) ÷ (24-hour cumulative permeation amount of the active ingredient through hairless mouse skin having an electrical resistance value of 7.0 kΩ or more and 10.0 kΩ or less) ≦ 5 ... formula 2
9. The absorption control agent is an ionic liquid having an anion represented by the following general formula (I) or (II): The quasi-drug or cosmetic according to claim 7 or 8, wherein the active ingredient is selected from the group consisting of glutathione, L-cysteine, tryptophan, histidine, nicotinamide, hydroxyproline, serine, arginine, alanine, γ-aminobutyric acid, and derivatives thereof, and pharmacologically acceptable salts thereof. 【Chemistry 2】 (In formula (II), R 1 represents a hydrogen atom or an acyl group; R 2 represents an alkyl group which may be substituted with a halogen atom, a halogen atom, a sulfo group, an aryl group, or an alkoxy group.
10. A therapeutic or preventive agent for a disease accompanied by stratum corneum damage, comprising the absorption controller according to claim 1 or 2 and an active ingredient.
Citation Information
Patent Citations
Pharmaceutical composition including temperature-responsive ionic liquid
WO2021070893A1
Cited By
Transdermal patch
WO2026168385A1
